BioNTech sees up to 17 billion eur in vaccine revenue this year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Pfizer (PFE) Asks FDA to Amend EUA and Include Booster for Everyone 18+, Analyst Sees Good Chances for Winning Approval and Upgrades BioNTech (BNTX) to Buy
November 11, 2021 9:01 AM ESTYesterday, Germany recommended only the Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NYSE: BNTX) for under the 30s as it causes fewer heart inflammations in younger people than the Moderna (NASDAQ: MRNA).
The committee also recommended pregnant women receive only the BioNTech/Pfizer vaccine.
In the meantime, two... More
BioNTech (BNTX) PT Lowered to $289 at Goldman Sachs
November 11, 2021 7:19 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $289.00 (from $433.00) while maintaining a Neutral rating.
The analyst commented, "While vaccine marketplace trends continue to provide tailwinds for mRNA-vaccine manufacturers, more hesitant management commentary around the endemic phase... More
